Education
About Us
Working with TipRanks
Follow Us
Glaukos (GKOS)
NYSE:GKOS
Earnings Data
Report Date
May 06, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.27Last Year’s EPS
-0.22Same Quarter Last Year
Strong Buy
Based on 14 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call reported multiple substantial positive developments: record Q4 and FY2025 revenue, strong iDose TR adoption and revenue (~$136M in 2025), FDA approval and active commercial launch progress for Epioxa, tangible early payer engagement and site deployments, and continued pipeline momentum across several programs. Challenges and near-term headwinds were acknowledged — including Q4 iDose sequential dynamics, expected transition volatility from Photrexa to Epioxa (temporary misc J-code impacts and prior-authorization delays), international competitive trialing, and higher OpEx to support launches. Overall, the positives (record results, robust product momentum, successful approval and launch activities, and clear guidance) materially outweigh the manageable and largely execution/timing-related lowlights.Company Guidance
Record Quarterly and Annual Revenue
Q4 2025 consolidated net sales of $143.1M (record) — up 36% reported / 34% constant currency vs. year-ago quarter. Full-year 2025 consolidated net sales of $507.4M (record) — up 32% vs. 2024.
Reaffirmed 2026 Guidance with Strong Growth Expectation
Company reaffirmed FY2026 net sales guidance of $600M–$620M, which implies >20% year-over-year growth at the midpoint and ~+$100M growth versus 2025 at the midpoint.
iDose TR Momentum and U.S. Glaucoma Growth
U.S. glaucoma Q4 net sales $86.4M — up 53% YoY, driven by iDose TR, which generated ~ $45M in Q4 and approximately $136M in 2025. Management expects U.S. glaucoma growth embedded in guidance to be ~30% YoY in 2026 driven entirely by iDose TR.
Epioxa FDA Approval and Commercial Launch Progress
FDA approval of Epioxa (topical corneal cross-linking without epithelial removal) announced in Q4; initial commercial launch activities underway with drug availability expected later in the current quarter. Positioned as first FDA‑approved topical, incision-free therapy for keratoconus.
Early Epioxa Market Access and Site Network Progress
Epioxa site-of-care network early deployment: O2n systems already deployed in locations covering nearly 50% of the U.S. population with a pipeline of systems expected to expand reach closer to 90%. Initial payer outreach engaged payers representing ~50% of commercially covered lives, including 4 of the top 5 commercial payers.
Encouraging Early Coverage and Coding Path
Several early positive coverage determinations reported (commercial and Medicaid). Permanent J-code submitted and expected effective July 2026; interim availability under a new technology miscellaneous J-code until then.
International and Corneal Franchise Growth
International glaucoma Q4 net sales $32.8M — up 18% reported / 13% constant currency YoY. Corneal health Q4 net sales $24.0M — up 12% YoY (Photrexa $21.4M). Management expects corneal health to grow modestly YoY in 2026 with volatility during the Photrexa→Epioxa transition.
Robust R&D and Clinical Pipeline Progress
Continued investment in R&D (> $1B invested since inception). Milestones: iStent infinite PMA enrollment completed; PRESERFLO 510(k) pivotal advancing; iDose TREX Phase IIb/III enrollment underway (Phase IIa showed IOP reductions of 8.6–10.8 mmHg through 3 months); iDose TRIO Phase IIIb commenced; iLink KC screening tool planned this year; ILution Phase II started; retinal GLK-401 FIH enrollment completed.
Capital Discipline with Operating-Leverage Target
CFO guidance to balance investments and revenues with goal of cash-flow breakeven/positive in 2026. OpEx expected to grow in the mid-teens YoY (management noted operating-leverage expectations despite increased spend for launches).
GKOS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GKOS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 17, 2026 | $106.64 | $121.00 | +13.47% |
Oct 29, 2025 | $77.09 | $87.80 | +13.89% |
Jul 30, 2025 | $94.05 | $86.09 | -8.46% |
Apr 30, 2025 | $94.25 | $83.54 | -11.36% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Glaukos (GKOS) report earnings?
Glaukos (GKOS) is schdueled to report earning on May 06, 2026, After Close (Confirmed).
What is Glaukos (GKOS) earnings time?
Glaukos (GKOS) earnings time is at May 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GKOS EPS forecast?
GKOS EPS forecast for the fiscal quarter 2026 (Q1) is -0.27.